Summary:
Marburg virus, a filovirus related to Ebolavirus, has caused multiple outbreaks across sub-Saharan Africa since its discovery in 1967, most recently in Rwanda in 2024 and Tanzania in 2025. With a case fatality rate of up to 88% and no currently licensed vaccines or therapeutics, development of a safe and effective vaccine remains an urgent global priority.
The Oxford Vaccine Group has developed a novel vaccine against Marburg virus disease, ChAdOx1 Marburg. Using the same viral vector technology as the Oxford/AstraZeneca COVID-19 vaccine, ChAdOx1 Marburg has shown promising preclinical results and is now being evaluated in a first-in-human clinical trial in Oxford. We will discuss pre-clinical data generated so far, the ongoing clinical trial and likely steps to licensure.

Bios:
Jennifer Cane is a Senior Postdoctoral Scientist in the Outbreak Pathogens group headed by Professor Teresa Lambe, within the Oxford Vaccine Group. Jennifer is an immunologist with interests in vaccine development against emerging pathogens.

Peter Skidmore is a clinician and DPhil candidate working on Marburg virus vaccine development under Prof Lambe within the Oxford Vaccine Group, and the lead clinical fellow on the first-in-human clinical trial of ChAdOx1 Marburg.